Development and external validation of a prostate health index-based nomogram for predicting prostate cancer.

To develop and externally validate a prostate health index (PHI)-based nomogram for predicting the presence of prostate cancer (PCa) at biopsy in Chinese men with prostate-specific antigen 4-10 ng/mL and normal digital rectal examination (DRE).

347 men were recruited from two hospitals between 2012 and 2014 to develop a PHI-based nomogram to predict PCa. To validate these results, we used a separate cohort of 230 men recruited at another center between 2008 and 2013. Receiver operator curves (ROC) were used to assess the ability to predict PCa. A nomogram was derived from the multivariable logistic regression model and its accuracy was assessed by the area under the ROC (AUC). PHI achieved the highest AUC of 0. 839 in the development cohort compared to the other predictors (p < 0. 001). Including age and prostate volume, a PHI-based nomogram was constructed and rendered an AUC of 0. 877 (95% CI 0. 813-0. 938). The AUC of the nomogram in the validation cohort was 0. 786 (95% CI 0. 678-0. 894). In clinical effectiveness analyses, the PHI-based nomogram reduced unnecessary biopsies from 42. 6% to 27% using a 5% threshold risk of PCa to avoid biopsy with no increase in the number of missed cases relative to conventional biopsy decision.

Scientific reports. 2015 Oct 16*** epublish ***

Yao Zhu, Cheng-Tao Han, Gui-Ming Zhang, Fang Liu, Qiang Ding, Jian-Feng Xu, Adriana C Vidal, Stephen J Freedland, Chi-Fai Ng, Ding-Wei Ye

Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, P. R. China. , Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, P. R. China. , Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, P. R. China. , State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, P. R. China. , Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, P. R. China. , State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, P. R. China. , Department of Surgery, Center for Integrated Research on Cancer and Lifestyle, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA. , Department of Surgery, Center for Integrated Research on Cancer and Lifestyle, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA. , SH Ho Urology Center, Department of Surgery, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, P. R. China. , Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe